Seres Therapeutics, Inc.
MCRB · NASDAQ
Bulios Fair Price
$2.06
49.4% downside
Current Price
$4.07
According to Bulios Fair Price, MCRB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome-based therapies. Their research and development efforts are centered around leveraging natural bacterial communities inhabiting the human body to treat various diseases. Seres Therapeutics particularly targets areas of the gastrointestinal tract, infectious diseases, and immune disorders. The company is developing microbiome-based therapeutics aimed at restoring the health of microbial communities in patients. Their research focuses on identifying and selecting appropriate bacterial strains and their application in treating specific diseases. Shares of Seres Therapeutics, Inc. (MCRB) could be suitable for investors seeking investments in the biotechnology sector with a focus on developing innovative microbiome-based drugs.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard N. Kender
Employees
66
Headquarters
Cambridge
Upcoming events
Earnings
Upcoming earnings report